Efficacy and safety of autologous adipose tissue-derived stem cell therapy for children with refractory Crohn's complex fistula: a Phase IV clinical study

Yu Jeong Cho; Hyunhee Kwon; Yong Jae Kwon; Kyung Mo Kim; Seak Hee Oh; Dae Yeon Kim

추천

검색

질문

자료유형: 학술저널

저자정보: Yu Jeong Cho (University of Ulsan College of Medicine) Hyunhee Kwon (University of Ulsan College of Medicine) Yong Jae Kwon (University of Ulsan College of Medicine) Kyung Mo Kim (University of Ulsan College of Medicine) Seak Hee Oh (University of Ulsan College of Medicine) Dae Yeon Kim (University of Ulsan College of Medicine)

저널정보: 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.101 No.1

발행연도: 2021.7

수록면: 58 - 64 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Autologous adipose tissue-derived stem cells (ASCs) have been proposed for patients with refractory Crohn disease, but research is lacking in pediatric patients. This Phase IV study evaluated the efficacy and safety of ASCs in children with refractory Crohn’s fistulae.
Methods: Patients with a refractory Crohn’s fistula who did not have conventional therapy for more than 3 months or with a recurrent complex Crohn’s fistula were included. All patients were at least 14 years old. Patients with infection, poor condition, or active Crohn disease with a disease activity index of 450 and above were excluded. Five patients were treated with ASCs from 2014 to 2015 in Asan Medical Center. ASC administration was adjusted according to fistula size (1 mL per ㎠). We evaluated the efficacy and safety 8 weeks after injection and followed patients for 6 months.
Results: Fistulae were healed in 4 patients by 8 weeks after ASC injection. Of these 4 patients, 1 had complete fistula closure and sustainability after 6 months. The other 3 with healing effects had less than 50% fistula closure by 6 months. None of these 4 patients have persistent fistulae. One patient had no healing effect, and seton ligation was performed 8 months after ASC injection. There were no adverse effects related to ASC administration.
Conclusion: ASC therapy is a simple and well-tolerated therapeutic option for children with refractory Crohn’s complex fistulae. Complete closure was well-sustained. However, more data from a larger number of patients are needed.

#Autologous stem cells #Mesenchymal stem cells #Pediatric Crohn's disease

참고문헌 (30)

참고문헌 신청

Xavier RJ / 2007 / Unravelling the pathogenesis of inflammatory bowel disease / Nature 448:427~434

Kim BJ / 2010 / Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience / Dig Dis Sci 55:1989~1995

Economou M / 2008 / New global map of Crohn’s disease: Genetic, environmental, and socioeconomic correlations / Inflamm Bowel Dis 14:709~720

Heyman MB / 2005 / Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry / J Pediatr 146:35~40

Vernier-Massouille G / 2008 / Natural history of pediatric Crohn’s disease: a population-based cohort study / Gastroenterology 135:1106~1113

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!